focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

Share Price Information for Team17 (TM17)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 265.00
Bid: 260.00
Ask: 270.00
Change: -3.00 (-1.12%)
Spread: 10.00 (3.846%)
Open: 262.50
High: 265.00
Low: 262.50
Prev. Close: 268.00
TM17 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Options

7 Jul 2020 07:00

RNS Number : 1843S
Team17 Group PLC
07 July 2020
 

7 July 2020

Team17 Group plc

("Team17", the "Group" or the "Company")

 

Exercise of options and admission to trading

 

Team17, a global games entertainment label, creative partner and developer of independent ("indie") premium video games, announces that, further to the exercise of options as part of the Team17 Group plc Long Term Incentive Plan, it has issued and allotted, subject to admission to trading on AIM ("Admission"), 70,946 new ordinary shares of £0.01 each (the "New Ordinary Shares").

 

Application for admission of the New Ordinary Shares to trading on AIM has been made and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on 10 July 2020. The New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu with the existing ordinary shares of £0.01 each in the capital of the Group, including the right to receive all future dividends and distributions declared, made or paid by reference to a record date falling after their issue.

 

Total Voting Rights

Following admission of the 70,946 new ordinary shares, the Group's issued share capital will comprise 131,473,222 ordinary shares of £0.01 each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Group under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Enquiries:

 

Team17 Group plc

Debbie Bestwick MBE, Chief Executive Officer

Mark Crawford, Chief Financial Officer

 

via Vigo Communications

+44 (0)20 7390 0238

GCA Altium (Nominated Adviser)

Phil Adams / Adrian Reed / Paul Lines

 

+44 (0)845 505 4343

Berenberg (Broker)

Chris Bowman / Toby Flaux / Marie Moy / Alix Mecklenburg-Solodkoff

 

+44 (0)20 3207 7800

Vigo Communications (Financial Public Relations)

Jeremy Garcia / Charlie Neish

team17@vigocomms.com

+44 (0)20 7390 0238

 

 

About Team17

Team17 is a leading games entertainment label and creative partner for independent ("indie") developers, focused on the premium, rather than free to play market, and creating games for the PC home computer market, the video games console market and the mobile and tablet gaming markets. Alongside developing the Company's own games in house ("first party IP"), Team17 also partners with independent developers across the globe to add value to their games in all areas of development and production alongside bringing them to market across multiple platforms for fixed percentage royalties ("third-party IP"). Since foundation in 1990, we have launched over 100 games, including the iconic Worms franchise, the Overcooked franchise, the Escapists franchise, Yooka-Laylee, Yoku's Island Express, My Time at Portia, Hell Let Loose and Blasphemous, making Team17 one of the most prolific developers and partners of games for the indie market.

 

 Visit www.team17.com for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEVQLFBBDLEBBV
Date   Source Headline
13th Mar 20234:49 pmRNSDirector/PDMR Shareholding
13th Mar 20239:05 amRNSNo Material Exposure to Silicon Valley Bank
2nd Mar 20237:00 amRNSNotice of Results & Analyst/Investor Presentations
13th Feb 20231:41 pmRNSDirector/PDMR Shareholding
31st Jan 20232:40 pmRNSHoldings in Company
19th Jan 20235:20 pmRNSHolding(s) in Company
18th Jan 20237:00 amRNSTrading Update
12th Jan 20239:04 amRNSDirector/PDMR Shareholding
10th Jan 20236:19 pmRNSHolding(s) in Company
9th Jan 20232:48 pmRNSTrading Update
13th Dec 20223:51 pmRNSDirector/PDMR Shareholding
17th Nov 20228:46 amRNSHolding(s) in Company
11th Nov 20225:13 pmRNSDirector/PDMR Shareholding
20th Oct 202212:11 pmRNSHolding(s) in Company
18th Oct 20221:42 pmRNSDirector/PDMR Shareholding
13th Sep 20224:32 pmRNSDirector/PDMR Shareholding
13th Sep 20227:00 amRNSHalf Year Results
5th Sep 20227:00 amRNSNotice of Results & Analyst/Investor presentations
12th Aug 20221:29 pmRNSDirector/PDMR Shareholding
18th Jul 20225:08 pmRNSHolding(s) in Company
15th Jul 20223:25 pmRNSHolding(s) in Company
14th Jul 20227:00 amRNSTrading Update
12th Jul 20223:56 pmRNSDirector/PDMR Shareholding
30th Jun 20223:58 pmRNSGrant of Options to Directors / PDMRs
29th Jun 20224:39 pmRNSResult of AGM
15th Jun 20227:00 amRNSDirector/PDMR Shareholding
14th Jun 20221:26 pmRNSHolding(s) in Company
1st Jun 202212:00 pmRNSPosting of Annual Report and Notice of AGM
20th May 20221:28 pmRNSDirector/PDMR Shareholding
17th May 20221:22 pmRNSDirector / PDMR Shareholding & Total Voting Rights
11th May 20225:36 pmRNSDirector/PDMR Shareholding
12th Apr 20225:48 pmRNSDirector/PDMR Shareholding
5th Apr 202211:06 amRNSSecond Price Monitoring Extn
5th Apr 202211:00 amRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSUnaudited Final Results
28th Mar 20224:40 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNSInvestor / Analyst call
11th Mar 20223:19 pmRNSDirector/PDMR Shareholding
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
1st Mar 20227:00 amRNSNotice of Results
14th Feb 20223:59 pmRNSHolding(s) in Company
11th Feb 20222:21 pmRNSDirector/PDMR Shareholding
1st Feb 20221:00 pmRNSDirector/PDMR Shareholding
20th Jan 20222:45 pmRNSHolding(s) in Company
18th Jan 20221:56 pmRNSDirector/PDMR shareholding
14th Jan 202212:40 pmRNSDirector/PDMR Shareholding
14th Jan 20227:00 amRNSResults of Placing
13th Jan 20224:36 pmRNSProposed Placing of New Ordinary Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.